Clinical Trial

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Completed
View on ClinicalTrials.gov →
Summary
Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-06-30
notable Primary completion moved earlier: 2026-06-30 -> 2025-12-30 2026-06-30
minor Completion moved earlier: 2026-06-30 -> 2025-12-30 2026-06-30
Trial Details
NCT Number NCT07313670
Lead Sponsor Muhammad Aamir Latif
Conditions Septic Shock
Enrollment 122 participants
Start Date 2025-07-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-29